Qureator, Inc. Qureator, Inc. Qureator, Inc. Qureator, Inc. Qureator, Inc. Qureator, Inc.
  • Home
  • Technologies
    • Disease Models
      • Cancer Metastasis
      • Cancer vTIME for Immunotherapy
      • Age-related Macular Degeneration (AMD)
      • Drug Induced Liver Injury (DILI)
      • Blood Brain Barrier (BBB)
    • Curiochips
    • AI
  • Therapeutic Applications
  • News
  • About
  • Contact
  • Home
  • Technologies
    • Disease Models
      • Cancer Metastasis
      • Cancer vTIME for Immunotherapy
      • Age-related Macular Degeneration (AMD)
      • Drug Induced Liver Injury (DILI)
      • Blood Brain Barrier (BBB)
    • Curiochips
    • AI
  • Therapeutic Applications
  • News
  • About
  • Contact
News & Publications
content-image
Qureator’s Historic FDA IND Approval Based on Human-Relevant Data Highlighted in The BIO
November 25, 2025
|
Tags : Press highlights ,
content-image
Qureator Achieves World’s First FDA IND Approval Using Only Human Vascularized Organoid Efficacy Data
October 27, 2025
|
Tags : Press highlights , Spotlight ,
content-image
Qureator’s Collaboration Highlighted in Korean Economic Daily
March 18, 2025
|
Tags : Press highlights ,
  • News
  • Publications
  • Public Biddings
  • All
  • Activities
  • Press highlights
  • Spotlight
Select Category
AllActivitiesPress highlightsSpotlight
주식회사 큐리오칩스 유세포분석기 공개입찰 공고문 안내
June 5, 2026
|
Tags :
content-image
Let’s Collaborate

Test your treatment with human tissue before putting it into human bodies.

Contact Us!
Qureator, Inc. Qureator, Inc.
contact-email
info@qureator.com
Get in touch
content-image
© Copyright 2026. All Rights Reserved.
Biotech Company Website by Thomas Digital
up